Thu, Jul 10, 2014, 4:53 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Merrimack Pharmaceuticals, Inc. (MACK) Message Board

  • hwsimpsonshero hwsimpsonshero Jul 30, 2013 2:07 PM Flag

    Four catalysts by end of year

    Anybody who keeps saying this is dead money until another deal or phenomenal data is released clearly doesn't understand the small-cap biotech sector.

    These prices are a gift if you're willing to hold for 4 months, at which point the stock will be significantly higher. At that point you should sell unless you are a fan of Russian roulette.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • If you are looking for a gift, you may want to take a look at VICL. Expecting result for Allovectin(R)
      • Top-line results from the company's Phase 3 registration trial of Allovectin(R), previously projected for release in the third quarter of 2013, are now expected to be released in August.
      • Following today's scheduled conference call, as described below, and extending until the release of top-line results, the company will enter a self-imposed quiet period during which time company management will not be interacting substantively with the investment community.
      This could have a DNDN run. By the way, VICL has no debt and has 70 million cash.
      Allovectin would be a monster. by the word monster, I mean billions. You may want to do some research and then read the articles.
      Upside, VICL could run up big time easy. There are no Guarantees, but it is worth the risk for me. I also like MACK and would be a buyer here.

      Sentiment: Strong Buy

    • I have a Bid request at $4.80, buying as much as I can.

 
MACK
6.85-0.16(-2.28%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.